UK regulators would likely have to fight to win jurisdiction over the $100 billion merger review of pharmaceutical giants Pfizer and AstraZeneca, according to competition experts.

The deal is so large, according to reports, that the European Commission would likely intervene if the UK’s Competition and Markets Authority tried to take …read more

Source: Global Competition Law Blogs